Phinergy: How Much of the Future Value Really Reaches Shareholders After Grants, Royalties, and Knowledge-Transfer Limits

What This Follow-Up Isolates

The main article argued that 2026 is still a proof year: Phinergy has to turn validation, first orders, and letters of intent into a stable commercial path. This follow-up isolates a different and less discussed layer: even if the commercial story works, not all of the future value flows automatically to shareholders.

The reason is threefold. The balance sheet already carries a NIS 21.434 million liability for government grants. Inside that layer sits one program, in oil alternatives, that imposes a 3% or 4% royalty not just on a specific product but on all company revenue. On top of that, the Israeli R&D law places limits on transferring know-how, licensing its use, and developing it outside Israel without prior approval.

This is not an accounting footnote. It is a value-capture layer. Anyone looking only at demand potential or at market size can miss that the key question in Phinergy is not only how much value can be created, but how much of it really remains after the state, through grants and their attached conditions, is already sitting on part of the path.

The Liability That Looks Distant but Already Sits in the Shareholder Layer

In the auditor's report, the measurement of the government-grant liability is identified as a key audit matter. That matters. The liability is not determined only by cash received in the past. It is measured against management assumptions around future royalty-bearing revenue, its timing, CPI, exchange rates, and discount rates. In other words, the liability moves together with the commercialization thesis. Part of the theoretical upside is already being pulled into the accounting estimate.

The year-end 2025 balance sheet makes the scale clear: NIS 415 thousand is classified as current, NIS 21.019 million as non-current, and together they make NIS 21.434 million. Against equity of NIS 39.113 million, that is already a layer equal to about 55% of equity. A superficial reading can go wrong twice here. First, the current portion is small, so the issue looks non-urgent. Second, in the absence of classic bank debt, it is easy to read the company as if it carries no meaningful economic claim ahead of shareholders. That would be a mistake. This is not bank debt, but it is still a real prior claim on future sales economics.

This chart shows why the burden is different from an ordinary paydown story. In 2025 the company paid only NIS 119 thousand of royalties, versus NIS 74 thousand in 2024. That is a small cash number. But the liability did not fall. It increased from NIS 19.209 million to NIS 21.434 million. Put differently, the accounting burden does not run off at the pace of a few tens of thousands of shekels. It is measured against a much broader future-commercialization picture. Anyone looking only at the cash royalties paid today is missing the economics of the state's claim already recorded on the balance sheet.

That leads to the critical distinction between liquidity and accessible value. In the short term this is not the same as a hard bank amortization schedule. The current portion is small. But over the horizon in which Phinergy does start scaling revenue, this becomes part of the economics of each additional shekel. So this is not mainly an immediate survivability issue. It is an early haircut on future value creation.

Not Every Future Shekel of Revenue Belongs Equally to Shareholders

The company details three main Israel Innovation Authority programs. In the first two, the classic R&D programs and the development-to-production transition program, cumulative grants received through the end of 2025 were NIS 6.603 million and NIS 2.980 million. In both, the royalty mechanism is relatively familiar: 3% of sales of products developed under the approved programs, or 4% when production takes place abroad, until the grants are repaid with interest.

The real analytical issue sits in the third program, the capital-investment encouragement program for oil alternatives. Under that program, cumulative grants received reached NIS 20.880 million, the largest part of the grant package described under the Innovation Authority. After the investors' warrants in that program expired or were cancelled, the grants were converted into an obligation to pay royalties at a rate of 3% or 4% on all company revenue.

That is the critical distinction. In the first two programs, the royalty base is sales of products developed under the specific program. In the oil-alternative program, the royalty base is much wider: all company revenue. So when thinking about future value at Phinergy, it is not enough to ask whether the company can sell. The right question is what share of that growth first has to pass through a royalty layer that is no longer tied only to one product.

The analytical implication is sharp. If the main thesis is that validation programs eventually open into broader commercialization, then part of that success is already pledged to a royalty mechanism. This is not necessarily a near-term cash drama. But it does mean the gap between accounting value or operating value and the value that truly remains with shareholders is smaller than an intuitive first read suggests.

There is another condition here that is easy to overlook. In these programs the royalty rate is 3%, or 4% when there is production abroad. The company also states that it received approval to manufacture abroad, and that such approval may affect the grant-repayment ceiling tied to sales royalties. So even if future commercialization requires an industrial footprint beyond Israel, the approval does not remove the payment layer. It only regulates it, and may change its scale.

Know-How Limits: Exporting Is Freer Than Licensing

The deepest point in this note is that money is not the only restriction. The Israeli R&D law restricts the know-how itself. Production based on know-how connected to Innovation Authority support is supposed to take place only in Israel, unless the authority approves otherwise in advance and in writing. Beyond that, the know-how, any right tied to it, and any sharing of it with others, including related parties and foreign parties, require prior written approval. Even pledging that know-how or placing it in trust requires approval.

This matters because it separates two very different commercialization routes. Marketing, exporting, and selling products developed on the basis of the know-how do not require Innovation Authority approval. By contrast, licensing the use of the know-how outside Israel, or transferring rights to use it for further development, sits in a different regime. There, payment to the authority can reach up to six times the funding received, plus interest, and in any case not less than the amount of funding received plus interest, net of royalties already paid.

The implication is that not every global path carries the same economics. If Phinergy sells systems, that is one layer. If part of the route to monetizing the opportunity runs through know-how licensing, deeper joint development, or use of the know-how outside Israel, an additional friction layer appears. This is the core of the follow-up. Phinergy's future value is not determined only by market size or by successful validation. It is also determined by the route through which the company chooses, or is forced, to commercialize the know-how.

One clarification is important here. The report does not say that every future commercial move necessarily triggers that kind of extraordinary payment. In fact, it explicitly says that exporting, marketing, and selling the products do not require Innovation Authority approval. But it also makes clear that once commercialization becomes know-how transfer, development licensing, or deeper global use of the know-how, the road is no longer frictionless.

The Restriction Is Not Theoretical

It is easy to read these legal sections as standard boilerplate. In Phinergy's case, the report shows that this issue has already appeared in practice. The company approached the Innovation Authority for approval to grant rights to use the know-how to the China JV and the India JV. For the China JV, approval was granted under the agreement without additional payment. For the India JV, the company granted a local manufacturing license, and for the development license only a principled approval was received, with payment terms to be set in the future based on the activity of the India JV and the company.

That example matters for two reasons. First, it proves that the know-how restrictions are not dormant language. The company has already had to manage them in real business situations. Second, it shows that the outcome is not binary. Sometimes there is approval without extra payment, and sometimes there is only a principled approval with payment terms to be determined later according to the actual activity. In other words, even when the authority does not block a route, it can still remain an economic participant in the commercialization path.

The right working table for shareholders therefore looks like this:

What Remains of the Upside if the Main Thesis Works

The conclusion here is not that grants are bad news. Quite the opposite. They helped fund development that a company of this size likely could not have carried on its own. Nor is the point that this liability is the same thing as an immediate liquidity crisis. The balance sheet does not show that.

But it does support a different and more precise conclusion: at Phinergy, future commercial success does not pass directly to shareholders. Before it reaches them, it goes through a royalty mechanism that is already defined, through an accounting estimate built off expected future revenue, and through restrictions on how the know-how can be commercialized outside Israel. So if the main article asked whether 2026 will establish the proof year, this follow-up adds the second question: even if proof arrives, how much of the value really remains after the grant, royalty, and know-how layers take their share?

The counter-thesis here is strong and deserves respect. One can argue that this is a perfectly reasonable price for a company still building its market, and that as long as royalties are paid only out of commercial success, this is a good problem rather than a bad one. There is logic in that view. But it still does not cancel the core point: between value created and value accessible to shareholders, Phinergy already has a very clear outside participation layer. Ignoring it means reading only half of the story.